Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-23
2008-09-23
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S385000, C546S193000, C548S317100
Reexamination Certificate
active
10471900
ABSTRACT:
Compounds of the formula (I) wherein z is SO2or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
REFERENCES:
patent: 2745875 (1956-05-01), Ehrhart et al.
patent: 3452040 (1969-06-01), Langis
patent: 3529019 (1970-09-01), Suh et al.
patent: 3849574 (1974-11-01), Suh et al.
patent: 4241073 (1980-12-01), Jamieson et al.
patent: 4315031 (1982-02-01), Vincent et al.
patent: 5068187 (1991-11-01), Takeichi et al.
patent: 5246943 (1993-09-01), Blankley et al.
patent: 5308853 (1994-05-01), Hodges et al.
patent: 5521187 (1996-05-01), Freyne et al.
patent: 5804593 (1998-09-01), Warpehoski et al.
patent: 5917790 (1999-06-01), Ohta et al.
patent: 5955435 (1999-09-01), Baxter et al.
patent: 6046214 (2000-04-01), Kristiansen et al.
patent: 6048841 (2000-04-01), Baxter et al.
patent: 6114361 (2000-09-01), Robinson et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6166041 (2000-12-01), Cavalla et al.
patent: 6218418 (2001-04-01), Pevarello et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6277987 (2001-08-01), Kukkola et al.
patent: 6291685 (2001-09-01), Junghans et al.
patent: 6329418 (2001-12-01), Cheng et al.
patent: 6339101 (2002-01-01), Ross et al.
patent: 6340691 (2002-01-01), Levin et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6890915 (2005-05-01), Sheppeck et al.
patent: 6906053 (2005-06-01), Sheppeck et al.
patent: 7078424 (2006-07-01), Hamilton et al.
patent: 2002/0006920 (2002-01-01), Robinson et al.
patent: 2002/0028835 (2002-03-01), Hu et al.
patent: 2002/0065219 (2002-05-01), Naidu et al.
patent: 2002/0091107 (2002-07-01), Madar et al.
patent: 2003/0130273 (2003-07-01), Sheppeck et al.
patent: 2004/0106659 (2004-06-01), Af Rosenschold
patent: 2004/0110809 (2004-06-01), Lepisto et al.
patent: 2004/0116486 (2004-06-01), Lepisto et al.
patent: 2004/0138276 (2004-07-01), Eriksson et al.
patent: 2004/0147573 (2004-07-01), Eriksson et al.
patent: 2004/0152697 (2004-08-01), Chan et al.
patent: 2004/0209874 (2004-10-01), Sheppeck et al.
patent: 2005/0019994 (2005-01-01), Chang
patent: 2005/0026990 (2005-02-01), Eriksson et al.
patent: 2005/0171096 (2005-08-01), Sheppeck et al.
patent: 2005/0245586 (2005-11-01), Henriksson et al.
patent: 2005/0256176 (2005-11-01), Burrows et al.
patent: 2006/0063818 (2006-03-01), Burrows et al.
patent: 2006/0276524 (2006-12-01), Henriksson et al.
patent: 212617 (1986-08-01), None
patent: 0486280 (1991-11-01), None
patent: 0 640 594 (1995-03-01), None
patent: 0709375 (1995-10-01), None
patent: 1149843 (2001-10-01), None
patent: WO95/14025 (1994-11-01), None
patent: WO 1996/27583 (1996-09-01), None
patent: WO98/50359 (1998-05-01), None
patent: WO99/06361 (1999-02-01), None
patent: WO99/42443 (1999-02-01), None
patent: WO99/24399 (1999-05-01), None
patent: WO 00/09103 (1999-08-01), None
patent: WO 00/35886 (1999-12-01), None
patent: WO99/62880 (1999-12-01), None
patent: WO 00/12477 (2000-03-01), None
patent: WO 00/12478 (2000-03-01), None
patent: WO 00/40577 (2000-07-01), None
patent: WO00/044770 (2000-08-01), None
patent: WO 00/75106 (2000-12-01), None
patent: WO 01/05756 (2001-01-01), None
patent: WO 01/12189 (2001-02-01), None
patent: WO 01/22363 (2001-03-01), None
patent: WO06/004532 (2006-01-01), None
patent: WO06/004533 (2006-01-01), None
U.S. Appl. No. 10/471,808.
Wernicke et al., (1996) J. Rheumatol. vol. 23, pp. 590-595.
Lindy et al., (1997) Arthritis Rheum., vol. 40, No. 8, pp. 1391-1399.
Whittaker et al., “Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors,” Chem. Rev., 1999, 99, 2735-2776, especially p. 2767.
Comber et al., “5,5-Disubstittued Hydantoins: Syntheses and Anti-HIV Activity,” J. Med. Chem., 1992, 35, 3567-3572, especially p. 3568.
Hautamaki et al., Science, 1997, 277, 2002-2004; Wernicke et al., (1996) J. Rheumatol. vol. 23, pp. 590-595; Lindy et al., (1997) Arthritis Rheum., vol. 40, No. 8, pp. 1391-1399.
Pyo et al., J. Clinical Investigation, 2000, 105, 1641-1649; Doherty, et al., Expert Opinion Ther. Patents, 2002, 12, 665-707.
Comber et al., “5,5-Disubstittued Hydantoins: Syntheses and Anti-HIV Activity,” J. Med. Chem., 1992, 35, 3567-3572, especially p. 3568.
Wernicke et al., (1996) J. Rheumatol. vol. 23, pp. 590-595.
Lindy et al., (1997) Arthritis Rheum., vol. 40, No. 8, pp. 1391-1399.
Whittaker et al., “Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors,” Chem. Rev., 1999, 99, 2735-2776, especially p. 2767, section 1.
Pyo et al., J. Clinical Investigation, 2000, 105, 1641-1649.
Periostat, a MMP inhibitor currently approved and marketed for periodontal disease in humans.
Doherty, et al., Expert Opinion Ther. Patents, 2002, 12, 665-707.
Comber et al., “5,5-Disubstittued Hydantoins: Syntheses and Anti-HIV Activity,” J. Med. Chem., 1992, 35, 3567-3572, especially p. 3568.
Hautamaki et al., Science, 1997, 277, 2002-2004; (b) rheumatoid arthritis (see Wernicke et al., (1996) J. Rheumatol. vol. 23, pp. 590-595 and Lindy et al., (1997) Arthritis Rheum., vol. 40, No. 8, pp. 1391-1399 and the specification page 3).
Whittaker et al., “Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors,” Chem. Rev., 1999, 99, 2735-2776, especially p. 2767, section 1, and reference 350 and 351 and Table 4 on p. 2768.
Pyo et al., J. Clinical Investigation, 2000, 105, 1641-1649; and (e) periodontal disease (see Periostat, a MMP inhibitor currently approved and marketed for periodontal disease in humans and Doherty, et al., Expert Opinion Ther. Patents, 2002, 12, 665-707).
STN International, File CAPLUS, CAPLUS accession No. 1968:506154, Doc. No. 69:106154, Lora-Tamayo, J. et al.: “Potential anticancer agents, VI. Sulfonic analogs of aspartic acid”, & An. Quim. (1968), 64(6), 591-606.
STN International, File CAPLUS, CAPLUS accession No. 1974:463633, Doc. No. 81:63633, Blaha, Ludvik et al.: “5-Methyl-5-phenoxymethyl-hydantoins”, & CS 151744, B, 19731119.
STN International, File CAPLUS, CAPLUS accession No. 1988:631020, Doc. No. 109:231020, Mitsui Toatsu Chemicals, Inc.: “Process for the preparation of 5-benzylhydantoins as intermediates for aromatic amino acids”: & JP, A2, 63079879, 19880409.
STN International, File CAPLUS, CAPLUS accession No. 1989:173366, Doc. No. 110:173366, Oh, Chang Hyun et al., “Synthesis of new hydantoin-3-acetic acid derivatives”, & Bull. Korean Chem. Soc. (1988), 9(4), 231-5.
STN International, File CAPLUS, CAPLUS accession No. 1990:138955, Doc. No. 112:138955, Crooks, Peter A. et al.: “Synthesis of 5-benzoyl-5-phenyl-and-5-(Phenylhydroxymethyl)-5-phenylhydantoins as potential anticonvulsants”; & J. Heterocycl. Chem. (1989), 26(4), 1113-17.
Chemical Abstracts, vol. 65, 1966, ABSTRACT No. 13684 h, M. Lora-Tamayo et al.: “Potential anticancer agents. I. Glutamine sulfonate analogs”, & Anales Real Soc. Espan. Fis. Quim (Madrid), Ser. B. 62(2), 173-86.
Banfield, J. E. et al., “Heterocyclic Derivatives of Guanidine. Part V. Reaction of Some Glycidic Esters with Guanidines”,The Journal of The Chemical Society, 511:2747-2756, (1963).
Belvisi, M. G. et al., “The role of matrix metalloproteinases (MMPs) in the patho-physiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?”,Inflammation Research, 52:95-100, (2003).
Borchers, Michael T. et al., “Acrolein-Induced MUC5ac Expression in Rat Airways”,The American Physiological Society, 274:L573-L581, (1998).
Carmeliet, Peter, “Proteinases in Cardiovascular Aneurysms and Rupture: Targets for Therapy?”,The Journal of Clinical Investigation, 105(11):1519-1520, (2000).
Dahan, Maurice et al., “Expression of Matrix Metalloproteinases in Healthy and Diseased Human Gingiva”,Journal of Clinical Periodontology, 28:128-136, (2001).
Doherty, Terence M. et al., “Therapeutic Developments in Matrix Metalloproteinase Inhibition”,Expert Opinion Ther. Patents, 12(5):665-70
Af Rosenschöld Magnus Munck
Eriksson Anders
Lepistö Matti
Lundkvist Michael
Zlatoidsky Pavol
Anderson Rebecca
AstraZeneca AB
Chung Susannah L.
Fish & Richardson P.C.
LandOfFree
Metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3948846